China accounts for roughly 7% of Illumina’s total annual revenue, or about $300 million, though it has continued to decline in that market in recent quarters.

Illumina's divestiture of GRAIL boosts financials, while strong gross margins and DNA sequencing growth drive potential. See ...

Illumina lowered its annual financial forecast and says it plans to cut about $100 million in costs after China banned imports of its gene sequencers last week. The San Diego maker of gene ...

Illumina on Monday lowered its annual forecast and said it plans to cut $100 million in spending after China announced a ban on imports of its genetic sequencing instruments.

China announced a ban on Tuesday on imports of genetic sequencers from U.S. medical equipment maker Illumina , just minutes after U.S. President Donald Trump's additional 10% tariff on Chinese ...

China banned the import of Illumina Inc. gene-sequencing machines as part of a wave of retaliatory measures against fresh US tariffs on all Chinese goods, deepening the US company’s woes in one ...

In recent years, Illumina has boasted of its footprint in China, where it has estimated that the DNA sequencing industry is growing faster than the global market. The company opened its first ...

Now Beijing is going further. Retaliating against the White House’s latest 10% tariff on all Chinese imports, China's government said Illumina will be barred from exporting gene sequencers to China.

Illumina’s shares fell more than 5% Tuesday on the Nasdaq. In naming Illumina and Calvin Klein parent PVH to the list, China accused the companies of violating standard market trading principles ...

When Illumina was placed on China’s blacklist last month, he noted that the company’s long-term financial outlook was not reliant on China. Related Articles.

China accounts for about 7% of Illumina's sales. Gene sequencers help determine the sequence of DNA or RNA, allowing scientists to study genetic variations associated with diseases and diagnose ...